Wyeth Licenses Osteoporosis Drug Targets From Galapagos
This article was originally published in The Pink Sheet Daily
Executive Summary
Wyeth agrees to second milestone stemming from 2003 agreement, selecting three novel Galapagos targets for osteoporosis.
You may also be interested in...
Pharma-Size That: Galapagos Expands RA Drug Development With Blockbuster J&J Deal
Alliance valued at over €1 billion includes potential landmark €60 million license on Galapagos' lead internal rheumatoid arthritis candidate GT418.
Pharma-Size That: Galapagos Expands RA Drug Development With Blockbuster J&J Deal
Alliance valued at over €1 billion includes potential landmark €60 million license on Galapagos' lead internal rheumatoid arthritis candidate GT418.
Wyeth’s Viviant “Approvable” For Prevention Of Postmenopausal Osteoporosis
Firm continues to plan an additional submission this year for an osteoporosis treatment claim.